Ovary Cancer clinical trials at UC Cancer
1 research study open to eligible people
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
open to eligible females ages 18 years and up
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Our lead scientists for Ovary Cancer research studies include Gottfried Konecny, MD.